CCO Oncology Podcast

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Presenters: Heather H. Cheng, MD, PhD Associate Professor Department of Medicine Division of Hematology and Oncology Attending Physician Department of Genitourinary Medical Oncology Fred Hutchinson Cancer Center Seattle, Washington Colin C. Pritchard, MD, PhD Co-Director Genetics and Solid Tumors Laboratory University of Washington Medical Center Professor Department of Laboratory Medicine and Pathology University of Washington Seattle, Washington Content based on an online CME program supported by an independent educational grant from Pfizer, Inc. Link to full program: https://bit.ly/3PFagxb

In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: Presenters: Sara M. Tolaney, MD, MPH Chief, Division of Breast Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Melinda Telli, MD Professor of Medicine Stanford University School of Medicine Director, Breast Cancer Program Stanford Cancer Institute Palo Alto, California Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc. Link to full program: https://bit.ly/49WxRBM

The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD Associate Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including a downloadable highlights slideset: https://bit.ly/48ecElW

This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including: Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD Associate Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including a downloadable highlights slideset: https://bit.ly/48ecElW

This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD Associate Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including a downloadable highlights slideset: https://bit.ly/48ecElW

In this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including: Presenters: Brian Slomovitz, MD, MS, FACOG Director Gynecologic Oncology Mount Sinai Medical Center Professor Obsterics and Gynecology Florida International University Member, Board of Directors GOG Foundation Uterine Cancer Lead GOG Partners Miami, Florida Keiichi Fujiwara, MD, PhD Professor of Gynecologic Oncology Saitama Medical University International Medical Center Hidaka, Japan Professor of OBGYN International University of Health and Welfare Narita, Japan This educational activity is supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, and Seagen. Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries: https://bit.ly/424E3Uq

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including: Presenter: Jacqueline S. Garcia, MD Assistant Professor of Medicine Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts Link to the full program here. https://bit.ly/47z8WCV

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: Presenters: Ana Marin-Niebla, MD, PhD Hematology Consultant, Lymphoma Unit Vall d’Hebron Institute of Oncology, Hematology Department Hospital Universitario Vall d’Hebron Barcelona, Spain Stephan Stilgenbauer, MD Medical Director Comprehensive Cancer Center Ulm Head, Early Clinical Trials Unit Head, Division of CLL Dept. of Internal Medicine III University Medical Center Ulm University Ulm, Germany Link to full program: https://bit.ly/3MNaUri

In this episode, Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, provide expert insights on new clinical trial data presented at the 2023 ESMO annual congress for endometrial, ovarian, and cervical cancers, including: Presenters: Ana Oaknin, MD, PhD Head of Gynaecologic Cancer Programme Department of Medical Oncology Vall d’ Hebron University Hospital Vall d’Hebron Institute of Oncology Barcelona, Spain Isabelle Ray-Coquard, MD, PhD President of the Gineco Group Centre Leon Bérard Laboratories RESHAPE Université Claude Bernard Lyon Est Lyon, France This educational activity is supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, and Seagen. Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries: https://bit.ly/424E3Uq

In this episode, Aakash Desai, MD; Narjust Florez, MD; and Paolo Tarantino, MD, discuss the biologic rationale and clinical development of agents targeting HER3 for the treatment of breast and lung cancers. The potential niche for HER3-targeted agents in these treatment landscapes is considered, with consideration of acquired resistance to previous targeted therapies and parallels to other approved antibody–drug conjugates. Their conversation covers clinical trial data from: Presenters: Aakash Desai, MD Affiliation awaiting contract Narjust Florez, MD Associate Director of The Cancer Care Equity Program Thoracic Medical Oncologist, Dana-Farber Cancer Institute Assistant Professor of Medicine, Harvard Medical School Boston, Massachusetts Paolo Tarantino, MD Advanced Research Fellow Breast Oncology Center Dana-Farber Cancer Institute Boston, Massachusetts Content based on an online CME program supported by an independent educational grant from Daiichi Sankyo, Inc. Link to full program: https://bit.ly/45UYsw3

In this episode, Dr Leslie Boyd and Adrienne Moore, a patient advocate and endometrial cancer survivor, discuss how healthcare professionals can partner with Black patients to improve the diagnosis and management of endometrial cancer (EC). Topics include: Presenters: Leslie R. Boyd, MD Associate Professor Department of Obstetrics and Gynecology at NYU Grossman School of Medicine Director of Division of Gynecologic Oncology Vice Chair of Gynecology Department of Obstetrics and Gynecology Laura and Isaac Perlmutter Cancer Center New York University Langone Health New York, New York Adrienne Moore, RT President and Board Member Endometrial Cancer Action Network for African-Americans Director of Peer Support, SISTER Study Research Coordinator, Gynecologic Oncology Department of Obstetrics and Gynecology University of Washington School of Medicine Seattle, Washington

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the ESGO 2023 Congress for cervical, endometrial, and ovarian cancers, including: TP53Presenters: Alexandra Leary, MD, PhD Co Director Medical Oncologist and Team Leader Gynecology Translational Research Lab Department of Medicine Gustave Roussy Cancer Center Paris, France Domenica Lorusso, MD, PhD Associate Professor Gynecologic Oncology Department Clinical Research Unit Fondazione Policlinico Gemelli IRCCS Rome, Italy This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab, and Seagen. Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries: https://bit.ly/424E3Uq

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: Presenters: Catherine C. Coombs, MD, MS Associate Clinical Professor Division of Hematology/Oncology, Department of Medicine UCI Health Orange, California Toby Eyre, MBChB, MD Honorary Senior Lecturer Hematology and Cancer University of Oxford Consultant Hematologist Department of Hematology Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust Oxford, United Kingdom

In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of: Presenters: Catherine C. Coombs, MD, MS Associate Clinical Professor Division of Hematology/Oncology, Department of Medicine UCI Health Orange, California Toby Eyre, MBChB, MD Honorary Senior Lecturer Hematology and Cancer University of Oxford Consultant Hematologist Department of Hematology Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust Oxford, United Kingdom

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of: Presenters: Catherine C. Coombs, MD, MS Associate Clinical Professor Division of Hematology/Oncology, Department of Medicine UCI Health Orange, California Toby Eyre, MBChB, MD Honorary Senior Lecturer Hematology and Cancer University of Oxford Consultant Hematologist Department of Hematology Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust Oxford, United Kingdom

In this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including: BRCA1/2Presenters: Kathleen Moore, MD, MS Associate Director, Clinical Research Department of Gynecologic Oncology Stephenson Cancer Center, University of Oklahoma Oklahoma City, Oklahoma Nicoletta Colombo, MD, PhD Associate Professor of Obstetrics and Gynecology European Institute of Oncology University of Milan-Bicocca Milan, Italy Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc. Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries: bit.ly/43Q5CBI

In this episode, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, provide expert insights on practice-changing data and other new findings presented at SGO 2023 in endometrial, cervical, and ovarian cancers, including: Presenters: David Scott Miller, MD, FACOG, FACS Amy and Vernon E. Faulconer Distinguished Chair in Medical Science Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics & Gynecology Fred F. Florence Bioinformation Center University of Texas Southwestern Medical Center Medical Director of Gynecologic Oncology Chair, Cancer Committee Parkland Health & Hospital System Dallas, Texas Linda Duska, MD, MPH Gynecologic Oncologist Department of OB GYN/Gynecologic Oncology University of Virginia School of Medicine Charlottesville, Virginia Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure Inc., and Seagen Inc. Link to full program: bit.ly/424E3Uq

In this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of: Presenters: Suzanne Lentzsch, MD, PhD Professor of Medicine Division of Hematology/Oncology Director, Multiple Myeloma and Amyloidosis Program Columbia University Medical Center New York, New York Joseph Mikhael, MD, MEd, FRCPC, FACP Professor Applied Cancer Research and Drug Discovery Translational Genomics Research Institute Phoenix, Arizona Chief Medical Officer International Myeloma Foundation HonorHealth Research Institute Scottsdale, Arizona Provided by Clinical Care Options, LLC in partnership with Smart Patients. Content supported by educational grants from AbbVie; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; and Regeneron Pharmaceuticals, Inc. Link to full program: bit.ly/41YEOO6

In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including: Presenters: John Mascarenhas, MD Professor of Medicine Icahn School of Medicine at Mount Sinai Director, Adult Leukemia Program Leader, Myeloproliferative Disorders Clinical Research Program Division of Hematology/Oncology Tisch Cancer Institute New York, New York Ruben A. Mesa, MD, FACP Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center Enterprise Senior Vice President, Atrium Health President, Enterprise Cancer Service Line Vice Dean for Cancer Programs, Wake Forest University School of Medicine Professor of Medicine, Wake Forest University School of Medicine Winston-Salem, North Carolina

In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of: BRCABRCABRCA Presenters: Banu Arun, MD Professor, Breast Medical Oncology Director, Clinical Cancer Genetics University of Texas MD Anderson Cancer Center Houston, Texas Allison Butts, PharmD, BCOP Pharmacist Manager, Oncology Director, PGY2 Oncology Residency Program UK HealthCare Assistant Adjunct Professor UK College of Pharmacy Lexington, Kentucky Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP Nurse Practitioner Breast Oncology Texas Oncology Baylor Sammons Cancer Center Dallas, Texas Content supported by educational grants from AstraZeneca and Merck Sharp & Dohme Corp. Link to full program: https://bit.ly/42VeUMM